ヒトインスリンの市場規模、シェア、成長分析：製品別、タイプ別、ブランド別、送達デバイス別、糖尿病別、地域別 - 産業予測 2025～2032年

ヒトインスリン市場規模は2023年に193億7,000万米ドルと評価され、2024年の202億8,000万米ドルから2032年には292億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.7％で成長する見通しです。

ヒトインスリン市場は糖尿病管理にとって極めて重要であり、1型糖尿病と2型糖尿病の影響を受ける数百万人に不可欠な治療を提供しています。国際糖尿病連合は、2019年の糖尿病成人4億6,300万人から2045年には7億人に増加すると予測しており、インスリンの需要は大幅に増加し、市場成長を牽引すると予想されます。製造技術、特に組換えDNA技術の開発により、より安全で効果的なインスリンが開発され、患者の受容性が高まっています。ヘルスケア組織、政府、NGO間の協力は、特に低所得地域におけるインスリンに対する認識を高め、入手しやすさを改善することを目的としています。しかし、高い製造コストと規制上の課題が、購入しやすい価格の妨げとなっています。アナログインスリンへのシフト、ペンやポンプのような革新的な送達デバイスの人気の高まり、AIの統合による補完は、治療アドヒアランスの向上と市場拡大における注目すべき動向です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

ヒトインスリン市場規模：製品別& CAGR（2025-2032）

• 市場概要
• HIドラッグ
• HIデリバリーデバイス

ヒトインスリン市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• インスリンアナログとバイオシミラー
  • 即効性
  • 長時間作用型
  • プレミックス
• HIバイオロジクス
  • 短時間作用型
  • 中間作用型
  • プレミックス

ヒトインスリン市場規模：ブランド別& CAGR（2025-2032）

• 市場概要
• HI類似体およびバイオシミラー
  • ランタス
  • ノボラピッド/ノボログ
  • ヒューマログ
  • その他のブランド
• HIバイオロジクス
  • アクトラピッド、インシュラタード、ミックスタード
  • ヒューマリン
  • インスマン

ヒトインスリン市場規模：送達デバイス別& CAGR（2025-2032）

• 市場概要
• ペン
  • 再利用可能
  • 使い捨て
• ペン針
  • 標準
  • 安全性
• 注射器

ヒトインスリン市場規模：糖尿病別 & CAGR（2025-2032）

• 市場概要
• 1型糖尿病
• 2型糖尿病

ヒトインスリン市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Biocon Limited（India）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Boehringer Ingelheim（Germany）
• Tonghua Dongbao Pharmaceutical Co., Ltd.（China）
• Wockhardt（India）
• Julphar（United Arab Emirates）
• Oramed Pharmaceuticals Inc.（United States）
• Adocia（France）
• MannKind Corporation（United States）
• Gan & Lee Pharmaceuticals（China）
• Ypsomed（Switzerland）
• Medtronic（Ireland）
• Dexcom（United States）
• Insulet Corporation（United States）
• Senseonics Holdings, Inc.（United States）

結論と提言

Human Insulin Market size was valued at USD 19.37 billion in 2023 and is poised to grow from USD 20.28 billion in 2024 to USD 29.29 billion by 2032, growing at a CAGR of 4.7% during the forecast period (2025-2032).

The human insulin market is crucial for diabetes management, providing essential treatment to millions impacted by type 1 and type 2 diabetes. With the International Diabetes Federation projecting an increase from 463 million diabetic adults in 2019 to 700 million by 2045, the demand for insulin is expected to rise significantly, driving market growth. Advances in production techniques, particularly recombinant DNA technology, have led to the development of safer and more effective insulin, enhancing patient acceptance. Collaborations among healthcare organizations, governments, and NGOs aim to raise awareness and improve insulin accessibility, especially in low-income regions. However, high production costs and regulatory challenges hinder affordability. The shift towards analog insulins and the rising popularity of innovative delivery devices like pens and pumps, supplemented by AI integration, are notable trends in enhancing treatment adherence and market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Insulin Market Segments Analysis

Global Human Insulin Market is segmented by Product, Type, Brand, Delivery Devices, Diabetes and region. Based on Product, the market is segmented into HI Drugs and HI Delivery Devices. Based on Type, the market is segmented into Insulin Analogs and Biosimilars and HI Biologics. Based on Brand, the market is segmented into HI Analogs and Biosimilars and HI Biologics. Based on Delivery Devices, the market is segmented into Pens, Pen Needles and Syringes. Based on Diabetes, the market is segmented into Type I Diabetes and Type II Diabetes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Human Insulin Market

The expanding incidence of diabetes globally serves as a critical catalyst for the human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, with predictions forecasting that this figure could soar to 700 million by 2045. This escalating diabetic population intensifies the need for insulin, thereby propelling market growth. Notably, nations such as China and India have experienced a notable rise in diabetes cases, attributed to shifts in lifestyle and dietary practices, which in turn has spurred an increased requirement for human insulin to manage these conditions effectively.

Restraints in the Human Insulin Market

The human insulin market faces several constraints primarily due to regulatory challenges and patent protections that limit competition and market entry. The process of acquiring regulatory approvals for new insulin products or biosimilars is demanding, necessitating thorough testing and adherence to strict guidelines, which can delay product availability. Furthermore, patent exclusivity on specific insulin formulations restricts the emergence of generic alternatives, thereby limiting choices for patients and hindering overall market expansion. For example, the exclusivity surrounding particular long-acting insulin analogs has effectively stifled the introduction of biosimilar options in the marketplace, exacerbating these constraints and impacting accessibility.

Market Trends of the Human Insulin Market

The Human Insulin market is currently experiencing a significant shift towards analog insulin formulations, driven by their superior benefits in diabetes management. Unlike traditional human insulin, which has limitations in terms of onset and duration, analog insulins provide rapid action and enhanced glycemic control, leading to improved patient outcomes. The rising adoption of long-acting analogs such as insulin glargine (Lantus) and insulin detemir (Levemir) has reshaped market dynamics, capturing substantial market share due to their favorable pharmacokinetic profiles. This trend underscores the growing preference among healthcare professionals and patients for precise insulin therapies, marking a transformative phase in diabetes treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Insulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• HI Drugs
• HI Delivery Devices

Global Human Insulin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Insulin Analogs and Biosimilars
  • Rapid-acting
  • Long-acting
  • Premixed
• HI Biologics
  • Short-acting
  • Intermediate-acting
  • Premixed

Global Human Insulin Market Size by Brand & CAGR (2025-2032)

• Market Overview
• HI Analogs and Biosimilars
  • Lantus
  • NovoRapid/Novolog
  • Humalog
  • Other Brands
• HI Biologics
  • Actrapid, Insulatard, and Mixtard
  • Humulin
  • Insuman

Global Human Insulin Market Size by Delivery Devices & CAGR (2025-2032)

• Market Overview
• Pens
  • Reusable
  • Disposable
• Pen Needles
  • Standard
  • Safety
• Syringes

Global Human Insulin Market Size by Diabetes & CAGR (2025-2032)

• Market Overview
• Type I Diabetes
• Type II Diabetes

Global Human Insulin Market Size & CAGR (2025-2032)

• North America (Product, Type, Brand, Delivery Devices, Diabetes)
  • US
  • Canada
• Europe (Product, Type, Brand, Delivery Devices, Diabetes)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Brand, Delivery Devices, Diabetes)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Brand, Delivery Devices, Diabetes)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Brand, Delivery Devices, Diabetes)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations